Journal
NUCLEAR MEDICINE AND BIOLOGY
Volume 31, Issue 8, Pages 1021-1031Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/j.nucmedbio.2004.06.002
Keywords
DUC18; CMS5 PET; DOTA; Cu-64; immunotherapy
Funding
- NCI NIH HHS [R24 CA86307, P50 CA94056, 1 R24 CA83060] Funding Source: Medline
Ask authors/readers for more resources
Increased understanding in the area of trafficking behavior of adoptively transferred tumor-specific T cells could help develop better therapeutic protocols. We utilized the DUC18/CMS5 tumor model system in conjunction with a microPET scanner to study the DUC18 T cell distribution pattern in spleens and lymph nodes in live mice. Anti-Thy1.2 antibodies conjugated to 1,4,7,10-tetraazacyclododecaneN,N',N,N-tetraacetic acid (DOTA) and radiolabeled with (CU)-C-64 were administered to three groups of BALB-Thy1.1 mice on days 4, 7, or 14 post-DUC18 T cell transfer. We were able to detect the transferred cells in all the major lymph nodes, spleens, and in tumors. Our findings suggest that tumor-specific T cells do not all preferentially localize to the tumors but they also home to all the major lymphoid organs; additionally the number of DUC18 T cells remains relatively constant during and after tumor elimination within each lymphoid organ. (C) 2004 Elsevier Inc. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available